论文部分内容阅读
阿糖胞苷(Ara-C)是近10年治疗急性非淋巴细胞白血病(ANLL)的主要药物,与其他化疗药物配用,初治患者完全缓解(CR)率一般可达40～60%。但存在相当部分的难治型及复发型病例,其治疗较棘手。随着初治病例缓解率的提高和生存期的延长,如何改善这两型的疗效,成为引人瞩目的课题。解决途径之一就是提高现有药物的剂量。大剂量Ara-C方案(HD Ara-C)首先
Ara-C is the main drug for the treatment of acute non-lymphocytic leukemia (ANLL) in recent 10 years. When used in combination with other chemotherapeutic drugs, the complete remission (CR) rate of newly diagnosed patients is generally 40-60%. But there are a considerable number of refractory and recurrent cases, the treatment is more difficult. With the initial treatment of remission rate increased and the survival of the extension of how to improve the efficacy of these two types has become a subject of considerable attention. One solution is to increase the dose of existing drugs. High-dose Ara-C regimen (HD Ara-C) First